IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1167/iovs.08-3152 on April 1, 2009
 (Investigative Ophthalmology and Visual Science. 2009;50:4273-4278.)
© 2009 by The Association for Research in Vision and Ophthalmology, Inc.
doi:10.1167/iovs.08-3152
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
iovs.08-3152v1
50/9/4273    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, R. W. J.
Right arrow Articles by Dick, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, R. W. J.
Right arrow Articles by Dick, A. D.

Steroid Refractory CD4+ T Cells in Patients with Sight-Threatening Uveitis

Richard W. J. Lee,1,2 Lauren P. Schewitz,2 Lindsay B. Nicholson,2,3 Colin M. Dayan,2 and Andrew D. Dick1,2,3

1From the Bristol Eye Hospital, Bristol, United Kingdom; and the 2Departments of Clinical Sciences South Bristol and 3Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

PURPOSE. A discrete subpopulation of steroid refractory (SR) CD4+ T cells has recently been identified in patients with SR ulcerative colitis (UC). The purpose of this study was to test whether this subpopulation is also present in patients with clinically defined SR uveitis. As interleukin (IL)-2 experimentally mediates the SR phenotype, the combined effects of dexamethasone (Dex) and a range of IL-2 targeting immunosuppressive agents were also investigated.

METHODS. Peripheral blood mononuclear cells (PBMCs) from 27 patients with uveitis and 4 normal volunteers were cultured for 5 days with CD3-CD28 beads. In vitro steroid refractivity or responsiveness was determined by the presence or absence of a subpopulation of SR CD4+ cells (as previously reported for UC) that continued to proliferate or not in the presence of Dex. The patients were concurrently classified by a masked investigator as having clinically SR (threshold for disease reactivation, ≥10 mg prednisone daily) or steroid sensitive (SS) disease.

RESULTS. There was 78% (21/27) agreement between the in vitro and clinical classifications of SR and SS disease ({kappa} coefficient = 0.56, P = 0.002). This finding corresponds to a positive predictive value of 90% and a negative predictive value of 71%. In normal volunteers, basiliximab, daclizumab, and AG490 achieved an equivalent augmentation of CD4+ cell suppression in combination with Dex.

CONCLUSIONS. As in UC, patients with SR uveitis have a subpopulation of SR CD4+ cells that are a potential target for intervention with anti–IL-2 therapies, including inhibitors of JAK/STAT signaling. The identification of SR T cells also has potential clinical application as a biomarker for SR disease.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the Association for Research in Vision and Ophthalmology